Caredx announces proposed draft lcd that affirms surveillance testing coverage for solid organ transplant rejection

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced the release of a proposed draft local coverage determination (lcd) related to molecular testing for solid organ allograft rejection. there is no change in current coverage and the draft lcd is open.
CDNA Ratings Summary
CDNA Quant Ranking